This study further demonstrated that the combination of the CD19 CAR with a monoclonal TIGIT-blocking antibody can lead to enhanced CAR-T cell function and improved efficacy against NHL [15]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.